This prestigious international accelerator program supports the development of next-generation venture capital leaders from Japan and promotes the creation of globally connected VC funds.
Dr. Kimura’s selection reflects his outstanding track record, including top-7 global ranking as a CVC leader in the pharmaceutical industry, deep syndication experience in Silicon Valley and Boston, a robust network spanning Japan, the U.S., and Europe, and a unique strategic focus on life sciences. His proven ability to collaborate with both government agencies such as AMED, JIC, and JST, and leading global investors further strengthened his candidacy.
Through this program, Dr. Kimura aims to establish a globally competitive fund that bridges Japan’s rich academic and clinical innovations with top-tier global LPs. His goal is to go beyond a simple cross-border bridge and build a next-generation VC model grounded in global standards.
He also envisions mobilizing capital at scale to support large-scale projects including equipment-heavy innovation such as BNCT. His vision is clear:
“Elevate Japanese technologies and projects to the global stage, evaluated under rigorous scientific and business standards.”
Currently, Dr. Kimura is in the process of launching The NeXus Fund, a cross-border venture fund focused on biotech and medical innovations across Japan, the U.S., and Europe. This accelerator will serve as a catalyst for advancing fund formation, LP outreach, and institutional scaling.
At Bloom X³, our vision is not merely to bridge Japan and the world, but to fuse and elevate Japan’s intellectual property into globally competitive innovations — creating a new kind of ecosystem through what we call a ‘Mix-Up Model.’
We believe this selection is a major milestone in that journey. Going forward, we will continue to share strategic insights and updates on our website and SNS channels.
If you are interested in co-creating a world-class life sciences ecosystem, we welcome your collaboration.
